Jeffrey Ryan Stewart's most recent trade in Abbvie Inc was a trade of 33,132 Common Stock, $0.01 par value done at an average price of $210.5 . Disclosure was reported to the exchange on March 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 210.54 per share. | 31 Mar 2025 | 33,132 | 53,234 (0%) | 0% | 210.5 | 6,975,611 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 25,700 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 31 Mar 2025 | 25,700 | 112,066 (0%) | 0% | 79.0 | 2,030,814 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 209.49 per share. | 31 Mar 2025 | 25,700 | 86,366 (0%) | 0% | 209.5 | 5,383,893 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 20,226 | 86,366 (0%) | 0% | 205.0 | 4,146,735 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 33,854 | 33,854 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 19,111 | 80,052 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 9,432 | 106,592 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 9,268 | 97,160 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 7,840 | 87,892 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 178.69 per share. | 18 Mar 2024 | 27,740 | 60,941 (0%) | 0% | 178.7 | 4,956,861 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.36 per share. | 18 Mar 2024 | 26,110 | 119,890 (0%) | 0% | 61.4 | 1,602,110 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 26,110 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 178.85 per share. | 18 Mar 2024 | 26,110 | 93,780 (0%) | 0% | 178.9 | 4,669,774 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 179.03 per share. | 18 Mar 2024 | 5,099 | 88,681 (0%) | 0% | 179.0 | 912,874 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 178.99 per share. | 28 Feb 2024 | 26,121 | 93,780 (0%) | 0% | 179.0 | 4,675,398 | Common Stock, $0.01 par value |
| AbbVie | Ryan Stewart Jeffrey | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 39,085 | 39,085 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 33,042 | 93,983 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Stewart Ryan Jeffrey | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 9,268 | 119,901 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 8,810 | 102,793 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Stewart Ryan Jeffrey | EVP, CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 7,840 | 110,633 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 152.27 per share. | 13 Mar 2023 | 31,315 | 60,941 (0%) | 0% | 152.3 | 4,768,335 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 152.30 per share. | 13 Mar 2023 | 21,810 | 92,256 (0%) | 0% | 152.3 | 3,321,663 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2023 | 21,810 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.86 per share. | 13 Mar 2023 | 21,810 | 114,066 (0%) | 0% | 54.9 | 1,196,497 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, COMMERCIAL OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 154.28 per share. | 28 Feb 2023 | 24,910 | 92,256 (0%) | 0% | 154.3 | 3,843,115 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, COMMERCIAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,111 | 35,111 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, COMMERCIAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 32,085 | 93,026 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, COMMERCIAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 8,812 | 109,324 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, COMMERCIAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 7,842 | 117,166 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, COMMERCIAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 7,486 | 100,512 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 159.20 per share. | 24 Mar 2022 | 27,690 | 60,941 (0%) | 0% | 159.2 | 4,408,375 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.88 per share. | 24 Mar 2022 | 27,690 | 88,631 (0%) | 0% | 58.9 | 1,630,387 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2022 | 27,690 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.54 per share. | 25 Feb 2022 | 17,093 | 82,429 (0%) | 0% | 149.5 | 2,556,087 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 148.49 per share. | 25 Feb 2022 | 12,659 | 63,541 (0%) | 0% | 148.5 | 1,879,779 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 147.43 per share. | 25 Feb 2022 | 6,229 | 76,200 (0%) | 0% | 147.4 | 918,327 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 149.04 per share. | 25 Feb 2022 | 2,600 | 60,941 (0%) | 0% | 149.0 | 387,493 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 37,215 | 37,215 | - | - | Option (Right to Buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 19,209 | 66,313 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 13,837 | 99,522 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 7,710 | 85,685 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 7,486 | 77,975 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 4,176 | 70,489 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 128.00 per share. | 15 Dec 2021 | 2,152 | 47,104 (0%) | 0% | 128 | 275,456 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.15 per share. | 10 Dec 2021 | 1,713 | 49,256 (0%) | 0% | 124.2 | 212,669 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Sale of securities on an exchange or to another person at price $ 108.59 per share. | 28 Feb 2021 | 13,773 | 50,969 (0%) | 0% | 108.6 | 1,495,576 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 107.74 per share. | 28 Feb 2021 | 10,957 | 64,742 (0%) | 0% | 107.7 | 1,180,507 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 43,478 | 43,478 | - | - | Option (right to buy) | |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 10,098 | 61,067 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 7,486 | 75,699 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 4,176 | 68,213 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 2,970 | 64,037 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2020 | 25,290 | 0 | - | - | Option (Right to buy) | |
| AbbVie | Jeffrey Ryan Stewart | EVP, Commercial Operations | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 29 Dec 2020 | 25,290 | 50,969 (0%) | 0% | 105 | 2,655,450 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | EVP, Commercial Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.42 per share. | 29 Dec 2020 | 25,290 | 76,259 (0%) | 0% | 51.4 | 1,300,412 | Common Stock, $0.01 par value |
| AbbVie | Jeffrey Ryan Stewart | SVP, US Commercial Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 108.67 per share. | 10 Dec 2020 | 1,791 | 50,969 (0%) | 0% | 108.7 | 194,628 | Common Stock, $0.01 par value |